No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison

• Main Authors: Roberta Gagliardini (Author), Alessandro Cozzi-Lepri (Author), Andrea Mariano (Author), Fabrizio Taglietti (Author), Alessandra Vergori (Author), Amina Abdeddaim (Author), Francesco Di Gennaro (Author), Valentina Mazzotta (Author), Alessandra Amendola (Author), Giampiero D'Offizi (Author), Fabrizio Palmieri (Author), Luisa Marchioni (Author), Pierluca Piselli (Author), Chiara Agrati (Author), Emanuele Nicastri (Author), Maria Rosaria Capobianchi (Author), Nicola Petrosillo (Author), Giuseppe Ippolito (Author), Francesco Vaia (Author), Enrico Girardi (Author), Andrea Antinori (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objectives: No specific treatment has been approved for COVID-19. Lopinavir/ritonavir (LPV/r) and hydroxychloroquine (HCQ) have been used with poor results, and a trial showed advantages of combined antiviral therapy vs. single antivirals. The aim of the study was to assess the effectiveness of the...